Overview

PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARĪ³ target genes in monocytes in losartan-treated patients.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
German Heart Institute
Collaborators:
Charite University, Berlin, Germany
Merck Sharp & Dohme Corp.
MSD SHARP and DOHME GMBH Haar Germany
Treatments:
Losartan
Criteria
Inclusion Criteria:

- Age: 19-80

- Sex: male or female

- Prior diagnosis of treated hypertension

- Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case);

- or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/
control).

Exclusion Criteria:

- Non-steroidal anti-inflammatory drugs (exception: Acetyl salicylic acid) for the past
21 days (due to structural homologies to glitazones, and activating effects on PPARĪ³)

- Therapy with glitazones for the past 21 days.